Targeted Proteomics for Quantification of Biomarkers and Target Engagement

Accurate and reproducible protein quantification is critical across the drug development pipeline, from early discovery to clinical trials, especially when monitoring biomarkers, pharmacodynamic effects, or target engagement. While widely used, affinity-based assays can be limited by single-epitope recognition, cross-reactivity, reagent variability, and sensitivity to matrix effects, particularly when targeting low-abundance proteins, isoforms, or PTMs. In addition, they are typically species-specific, which can limit their applicability in preclinical research.

Biognosys’ MS-based targeted proteomics platform, TrueSignature, enables absolute, antibody-independent quantification at the peptide level. Custom panels are optimized for sensitivity and specificity, supporting robust, scalable assays that transfer reliably across species and sample types. Delivered as a contract research service with optional GCP-compliant validation, the platform provides high-quality quantitative data with rapid turnaround and broad applicability in translational and clinical research.

Download the flyer to learn more:

Download Flyer